PLX - Protalix BioTherapeutics, Inc.
| Previous Close | 0.4500 |
| Open | 0.4449 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.4140 - 0.4467 |
| 52 Week Range | 0.3800 - 0.8300 |
| Volume | 556,611 |
| Avg. Volume | 763,998 |
| Market Cap | 62.296M |
| Beta (3Y Monthly) | 3.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3350 |
| Earnings Date | Mar 10, 2016 - Mar 14, 2016 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.30 |
- Zacks•5 days ago
Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 days ago
Protalix: 3Q Earnings Snapshot
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...
- GlobeNewswire•5 days ago
Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update
CARMIEL, Israel, Nov. 07, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- Zacks•12 days ago
Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•14 days ago
Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018
CARMIEL, Israel, Oct. 29, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
- GlobeNewswire•26 days ago
New Research: Key Drivers of Growth for Cenovus Energy, Protalix BioTherapeutics, Rayonier Advanced Materials, B2Gold, Match Group, and Qudian Inc. Sponsored ADR — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Benzinga•last month
The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...
- GlobeNewswire•last month
Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A.
- Benzinga•last month
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs
Biotech shares saw further momentum last week, following up on the gains of the previous two weeks. Will the momentum continue in the upcoming week? Here are the catalytic events that could drive the sector. ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.
- GlobeNewswire•2 months ago
Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa to pegunigalsidase alfa. A deterioration trend in patients’ kidney function on agalsidase alfa was ...
- GlobeNewswire•2 months ago
Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018
CARMIEL, Israel, Sept. 17, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
- GlobeNewswire•3 months ago
Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Mr. Moshe Manor, the Company’s President and Chief Executive Officer, will provide a corporate overview on Wednesday, September 5 at 2:10 pm ET and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
- GlobeNewswire•3 months ago
Research Report Identifies Nomad Foods, AutoNation, Entercom Communications, IMAX, Protalix BioTherapeutics, and Yamana Gold with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nomad ...
- Zacks•3 months ago
Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.•3 months ago
Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)?
In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...
- Associated Press•3 months ago
Protalix: 2Q Earnings Snapshot
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...
- ACCESSWIRE•3 months ago
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Protalix Biotherapeutics, Inc. (NYSE: PLX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...
- ACCESSWIRE•3 months ago
Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).
Market Realist•4 months agoWhy Protalix Expanded Partnership with Chiesi
On July 24, Protalix BioTherapeutics (PLX) expanded its partnership with Chiesi Farmaceutici. The expansion of the agreement allows Chiesi Farmaceutici exclusive US license for the development and commercialization of PRX-102 (pegunigalsidase alfa), which is Protalix’s modified version of the recombinant alpha-galactosidase-A protein. In October 2017, Protalix and Cheisi entered an exclusive partnership for the development and commercialization of PRX-102 outside the US for the treatment of individuals with Fabry disease.
- Benzinga•4 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...
